FZ-AD005 not checked
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Every 21 days for 1 cycle. Subjects will receive an intravenous infusion of FZ-AD005 until confirmed progression, unaccepted toxicity, or any criterion for withdrawal from the study.”In the company’s words, NCT06424665 on ClinicalTrials.gov
- Tested for
- Advanced Solid Tumor, SCLC(Small Cell Lung Cancer) or LCNEC (Large Cell Neuroendocrine Carcinoma), High Grade Glioma (III or IV), Diffuse Midline Glioma (DMG), Glioblastoma (GBM)
- Main trialPhase 1
- “A First-in-Human, Open Label, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of FZ-AD005 in Patients with Advanced Solid Tumors.”In the company’s words, NCT06424665 on ClinicalTrials.gov
Other drugs for Advanced Solid Tumor, SCLC(Small Cell Lung Cancer) or LCNEC (Large Cell Neuroendocrine Carcinoma)
- PembrolizumabMerck & Co. · Phase 3
- Izalontamab brengitecanSichuan Baili (Biokin, SystImmune) · Bristol Myers Squibb · Phase 3
- Nanocrystalline Megestrol AcetateChangchun GeneScience Pharmaceutical Co., Ltd. · Phase 3
- IvonescimabAkeso · Summit Therapeutics · Phase 3
- Tambotatug pelitecanMediLink Therapeutics (Suzhou) Co., Ltd. · Phase 3
- ZG006Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Phase 3
Coming up1
- 1 Dec 2027Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Recruiting | 1 Aug 2026 | A Study of FZ-AD005 in Patients With Advanced Solid Tumors | |
| Phase 1Not yet recruiting | 1 Dec 2027 | A Phase I Study of FZ-AD005 in Patients With High-Grade Glioma (HGG) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026